(Q42485644)

1 November 2017

title

The effects of rosiglitazone and metformin on inflammation and endothelial dysfunction in patients with type 2 diabetes mellitus (English)

1 reference

1 November 2017

0 references

1 reference

1 reference

1 reference

Evren Fidan

1

1 reference

1 November 2017

H Onder Ersoz

2

1 reference

1 November 2017

Mustafa Yilmaz

3

1 reference

1 November 2017

Hulya Yilmaz

4

1 reference

1 November 2017

Mustafa Kocak

5

1 reference

1 November 2017

Caner Karahan

6

1 reference

1 November 2017

Cihangir Erem

7

1 reference

1 November 2017

language of work or name

1 reference

23 March 2011

1 reference

1 November 2017

1 reference

1 November 2017

volume

48

1 reference

1 November 2017

issue

4

1 reference

1 November 2017

page(s)

297-302

1 reference

https://scigraph.springernature.com/pub.10.1007/s00592-011-0276-y

1 November 2017

exact match

0 references

cites work

Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0276-Y

Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0276-Y

Insulin resistance and antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0276-Y

Insulin resistance, diabetes and cardiovascular risk: approaches to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0276-Y

Remnant-like particle cholesterol, triglycerides, and insulin resistance in nonobese Japanese type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0276-Y

Diagnosing insulin resistance in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0276-Y

Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0276-Y

Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0276-Y

Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0276-Y

Soluble E-selectin, leptin, triglycerides, and insulin resistance in nonobese Japanese type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0276-Y

Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0276-Y

Inflammatory responses underlying the microvascular dysfunction associated with obesity and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0276-Y

Effect of pioglitazone on systemic inflammation is independent of metabolic control and cardiac autonomic function in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0276-Y

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0276-Y

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0276-Y

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0276-Y

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0276-Y

Effect of Rosiglitazone on Endothelial Function and Inflammatory Markers in Patients With the Metabolic Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00592-011-0276-Y

10.1007/S00592-011-0276-Y

21 January 2018

Identifiers

DOI

1 reference

1 November 2017

1 reference